Rheumatoid arthritis: Pathophysiology and Implications for Therapy

New England Journal of Medicine

Volumn 322, Issue 18, 1990, Pages 1277-1289

  Epstein, Franklin H ^a   Harris, Edward D ^b  

^a Stanford University School of Medicine ^*

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; CYCLOSPORIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY;

HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY INJURY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; HUMAN; MOLECULAR SEQUENCE DATA;

EID: 0025304539     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199005033221805     Document Type: Review

References (160)

1. Benedek TG. A century of American rheumatology. Ann Intern Med 1987; 106: 304–12.
2. Rose HM, Ragan C, Pearce E, Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1948; 68: 1–6.
3. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1: 1108–11.
4. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037–41.
5. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously — predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841–5.
6. Mitchell DM, Fries JF. An analysis of the American Rheumatism Association criteria for rheumatoid arthritis. Arthritis Rheum 1982; 25: 481–7.
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
8. McDermott M, McDevitt H. The immunogenetics of rheumatic diseases. Bull Rheum Dis 1988; 38: 1–10.
9. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205–13.
10. Winchester RJ, Gregersen PK. The molecular basis of susceptibility to rheumatoid arthritis: the conformational equivalence hypothesis. Springer Semin Immunopathol 1988; 10: 119–39.
11. Gregersen PK, Shen M, Song QL, et al. Molecular diversity of HLA–DR4 haplotypes. Proc Natl Acad Sci U S A 1986; 83: 2642–6.
12. Nepom GT, Byers P, Seyfried C, et al. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 1989; 32: 15–21.
13. Zoschke D, Segall M. Dw subtypes of DR4 in rheumatoid arthritis: evidence for a preferential association with Dw4. Hum Immunol 1986; 15: 118–24.
14. Mengle-Gaw L, Conner S, McDevitt HO, Fatham CG. Gene conversion between murine class II major histocompatibility complex loci: functional and molecular evidence from the bm12 mutant. J Exp Med 1984; 160: 1184–94.
15. Calin A, Elswood J, Klouda PT. Destructive arthritis, rheumatoid factor, and HLA–DR4: susceptibility versus severity, a case–control study. Arthritis Rheum 1989; 32: 1221–5.
16. Venables PJW. Infection and rheumatoid arthritis. Curr Opin Rheumatol 1989; 1: 15–20.
17. Phillips PE. Evidence implicating infectious agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Clin Exp Rheumatol 1988; 6: 87–94.
18. Alspaugh MA, Henle G, Lennette ET, Henle W. Elevated levels of antibodies to Epstein–Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest 1981; 67: 1134–40.
19. Venables P. Epstein–Barr virus infection and autoimmunity in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 265–9.
20. Slaughter L, Carson DA, Jensen FC, Holbrook TL, Vaughn JH. In vitro effects of Epstein–Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. J Exp Med 1978; 148: 1429–34.
21. Yao QY, Rickinson AB, Gaston JS, Epstein MA. Disturbance of the Epstein–Barr virus-host balance in rheumatoid arthritis patients: a quantitative study. Clin Exp Immunol 1986; 64: 302–10.
22. Depper JM, Zvaifler NJ. Epstein–Barr virus: its relationship to the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1981; 24: 755–61.
23. Silverman SL, Schumacher HR. Antibodies to Epstein–Barr viral antigens in early rheumatoid arthritis. Arthritis Rheum 1981; 24: 1465–8.
24. Roudier J, Rhodes G, Petersen J, Vaughan JH, Carson DA. The Epstein–Barr virus glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and rheumatoid arthritis. Scand J Immunol 1988; 27: 367–71.
25. Roudier J, Petersen J, Rhodes GH, et al. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA–Dw4 DR beta-1 chain and the Epstein–Barr virus glycoprotein gp110. Proc Natl Acad Sci U S A 1989; 86: 5104–8.
26. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR. Bacon PA. Human parvovirus arthropathy. Lancet 1985; 1: 419–21.
27. Cohen BJ, Buckley MM, Clewley JP, Jones VE, Puttick AH, Jacoby RK. Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis 1986; 45: 832–8.
28. Naides SJ, Field EH. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med 1988; 148: 2587–9.
29. Simpson RW, McGinty L, Simon L, Smith CA, Godszeki CW, Boyd RJ. Association of parvoviruses with rheumatoid arthritis of humans. Science 1984; 223: 1425–8.
30. van Eden W, Thole JE, van der Zee R, et al. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988; 331: 171–3.
31. Polla BS. A role for heat shock proteins in inflammation? Immunol Today 1988; 9: 134–7.
32. Tsoulfa G, Rook GA, Van-Embden JD, et al. Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 118–23.
33. Holoshitz J, Koning F, Coligan JE, DeBruyn J, Strober S. Isolation of CD4– CD8– mycobacteria-reactive T lymphocyte clones from rheumatoid arthritis synovial fluid. Nature 1989; 339: 226–9.
34. Stuart JM, Townes AS, Kang AH. Collagen autoimmune arthritis. Annu Rev Immunol 1984; 2: 199–218.
35. Jasin HE. Abnormalities of immune regulation in the connective tissue diseases. Semin Arthritis Rheum 1983; 13: Suppl: 94–8.
36. Rowley M, Tait B, Mackay IR, Cunningham T, Phillips B. Collagen antibodies in rheumatoid arthritis: significance of antibodies to denatured collagen and their association with HLA–DR4. Arthritis Rheum 1986; 29: 174–84.
37. Choi EK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR. Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes. Ann Rheum Dis 1988; 47: 313–22.
38. Mottonen T, Hannonen P, Oka M, et al. Antibodies against native type II collagen do not precede the clinical onset of rheumatoid arthritis. Arthritis Rheum 1988; 31: 776–9.
39. Jasin HE. Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1985; 28: 241–8.
40. Parekh RB, Dwek RA, Sutton BJ, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985; 316: 452–7.
41. Axford JS, Mackenzie L, Lydyard PM, Hay FC, Isenberg DA, Roitt IM. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 1987; 2: 1486–8.
42. Carson DA, Chen PP, Kipps TJ, et al. Idiotypic and genetic studies of human rheumatoid factors. Arthritis Rheum 1987; 30: 1321–5.
43. Silverman GJ, Goldfien RD, Chen P, et al. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors: implications for structural and genetic basis of autoantibodies in humans. J Clin Invest 1988; 82: 469–75.
44. Moxley G. DNA polymorphism of immunoglobulin kappa confers risk of rheumatoid arthritis. Arthritis Rheum 1989; 32: 634–7.
45. Moxley. Immunoglobulin kappa genotype confers risk of rheumatoid arthritis among HLA–DR4 negative individuals. Arthritis Rheum 1989; 32: 1365–70.
46. Morel PA, Horn GT, Budd RC, Erlich HA, Fathman CG. Shared molecular markers of genetic predisposition to seropositive rheumatoid arthritis. Hum Immunol 1990; 27: 90–9.
47. Stamenkovic I, Stegagno M. Wright KA, et al. Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A 1988; 85: 1179–83.
48. Koch AE, Polverini PJ, Leibovich SJ. Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum 1986; 29: 471–9.
49. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–7.
50. Montesano R, Vassalli J-D, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 1986; 83: 7297–301.
51. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986; 261: 2814–8.
52. Cavender D, Haskard D, Yu C-L, et al. Pathways to chronic inflammation in rheumatoid synovitis. Fed Proc 1987; 46: 113–7.
53. Yu C-L, Haskard DO, Cavendar D, et al. Human gamma interferon increases the binding of T lymphocytes to endothelial cells. Clin Exp Immunol 1985; 62: 554–60.
54. Cavender DE, Haskard DO, Joseph B, Ziff M. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol 1986; 136: 203–7.
55. Cavender DE, Edelbaum D, Ziff M. Endothelial cell activation induced by tumour necrosis factor and lymphotoxin. Am J Pathol 1989; 134: 551–60.
56. Jalkanen S, Steere achéal, Fox RI, Butcher EC. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 1986; 233: 556–8.
57. Pitzalis C, Kingsley G, Haskard D, Panayi G. The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion. Eur J Immunol 1988; 18: 1397–404.
58. van Boxel JA, Paget SA. Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med 1975; 293: 517–20.
59. Pitzalis C, Kingsley G, Murphy J, Panayi G. Abnormal distribution of the helper-inducer and suppressor-induced T-lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol 1987; 45: 252–8.
60. Lasky HP, Bauer K, Pope RM. Increased helper inducer and decreased suppressor inducer phenotypes in the rheumatoid joint. Arthritis Rheum 1988; 31: 52–9.
61. Pitzalis C, Kingsley G, Lanchbury JS, Murphy J, Panayi GS. Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for “frustrated” activation. J Rheumatol 1987; 14: 662–6.
62. Lipsky PE. The control of antibody production by immunomodulatory molecules. Arthritis Rheum 1989; 32: 1345–55.
63. Bonagura VR, Wedgwood JF, Agostino N, et al. Seronegative rheumatoid arthritis, rheumatoid factor cross reactive idiotype expression, and hidden rheumatoid factors. Ann Rheum Dis 1989; 48: 488–95.
64. Harris ED Jr. Pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1989:905–42.
65. Zuraw BL, O'Hair CH, Vaughn JH, Mathison DA, Curd JG, Katz DH. Immunoglobulin E-rheumatoid factor in the serum of patients with rheumatoid arthritis, asthma, and other diseases. J Clin Invest 1981; 68: 1610–3.
66. Pope RM, Teller DC, Mannik M. The molecular basis of self-association of antibodies to IgG (rheumatoid factor) in rheumatoid arthritis. Proc Natl Acad Sci U S A 1974; 71: 517–21.
67. Shiozawa S, Jasin HE, Ziff M. Absence of immunoglobulins in rheumatoid cartilage-pannus junctions. Arthritis Rheum 1980; 23: 816–21.
68. Krane SM, Goldring MB, Goldring SR. Cytokines. In: Cell and molecular biology of vertebrate hard tissues. Ciba Foundation symposium no. 136. New York: John Wiley, 1988:239–56.
69. Firestein GS, Xu W-D, Townsend K, et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988; 168: 1573–86.
70. Miyasaka N, Sato K, Goto M, et al. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum 1988; 31: 480–6.
71. Firestein GS, Alvaro-Gracia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol (in press).
72. Hasler F, Dayer J-M. Diminished IL-2-induced gamma-interferon production by unstimulated peripheral-blood lymphocytes in rheumatoid arthritis. Br J Rheumatol 1988; 27: 15–20.
73. Pope RM, McChesney L, Talal N, Fischbach M. Characterization of the defective autologous mixed lymphocyte response in rheumatoid arthritis. Arthritis Rheum 1984; 27: 1234–44.
74. Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB. Analysis of the defects responsible for the impaired regulation of Epstein–Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation. J Exp Med 1983; 157: 173–88.
75. Hasler. Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. J Immunol 1983; 131: 768–72.
76. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughn JH. Release of lymphokines after infection with Epstein Barr virus in vitro. II. A monocyte-dependent inhibitor of interleukin 1 downregulates the production of interleukin 2 and interferon-gamma in rheumatoid arthritis. J Immunol 1986; 136: 3643–8.
77. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. Embo J 1987; 6: 1899–904.
78. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261: 4337–45.
79. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 1988; 140: 3026–32.
80. Fava R, Olsen N, Keski-Oja J, Moses H, Pincus T. Active and latent forms of transforming growth factor β activity in synovial effusions. J Exp Med 1989; 169: 291–6.
81. Dayer J-M, Seckinger P. Natural inhibitors and antagonists of interleukin-1. In: Bomford R, Henderson B, eds. Interleukin-1, inflammation and disease. New York: Elsevier Science, 1989:283–302.
82. Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA. Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheumatol 1985; 12: 406–11.
83. Levine JD, Goetzl EJ, Basbaum AI. Contribution of the nervous system to the pathophysiology of rheumatoid arthritis and other polyarthritides. Rheum Dis Clin North Am 1987; 13: 369–83.
84. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988; 241: 1218–21.
85. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987; 235: 893–5.
86. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol 1978; 120: 109–15.
87. Lee TC, Snyder F. Function, metabolism and regulation of platelet activating factor and related ether lipids. In: Kuo JF, ed. Phospholipids and cellular regulation. Boca Raton, Fla.: CRC Press, 1985:1–39.
88. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264–5.
89. Korchak HM, Vienne K, Rutherford LE, Weissmann G. Neutrophil stimulation: receptor, membrane, and metabolic events. Fed Proc 1984; 43: 2749–54.
90. Henson PM, Johnston RB Jr. Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J Clin Invest 1987; 79: 669–74.
91. Hibbs MS, Hasty KA, Kang AH, Mainardi CL. Secretion of collagenolytic enzymes by human polymorphonuclear leukocytes. Coll Relat Res 1984; 4: 467–77.
92. Elmgreen J, Nielsen OH, Ahnfelt-Rønne I. Enhanced capacity for release of leucotriene B4 by neutrophils in rheumatoid arthritis. Ann Rheum Dis 1987; 46: 501–5.
93. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365–76.
94. Bevilacqua MP, Stengelin S, Gimbrone MA Jr. Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160–5.
95. Gimbrone MA Jr, Obin MS, Brock AF, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 1989; 246: 1601–3.
96. Elmgreen J, Hansen TM. Subnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: relation to complement catabolism and disease extent. Ann Rheum Dis 1985; 44: 514–8.
97. Goldstein IM, Weissmann G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974; 113: 1583–8.
98. Van De Putte LB, Hegt VN, Overbeek TE. Activators and inhibitors of fibrinolysis in rheumatoid and nonrheumatoid synovial membranes: a histochemical study. Arthritis Rheum 1977; 20: 671–8.
99. Werb Z, Mainardi CL, Vater CA, Harris ED Jr. Endogenous activation of latent collagenase by rheumatoid synovial cells: evidence for a role of plasminogen activator. N Engl J Med 1977; 296: 1017–23.
100. Okada Y, Harris ED Jr, Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts: purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem 1988; 254: 731–41.
101. Hollingsworth JW, Siegel ER, Creasey WA. Granulocyte survival in synovial exudate of patients with rheumatoid arthritis and other inflammatory joint disease. Yale J Biol Med 1967; 39: 289–96.
102. Harris ED Jr, Faulkner CS II, Brown FE. Collagenolytic systems in rheumatoid arthritis. Clin Orthop 1975; 110: 303–16.
103. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973; 2: 96–100.
104. Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976; 35: 357–60.
105. Fleming A, Benn RT, Corbett M, Wood PH. Early rheumatoid disease. II. Patterns of joint involvement. Ann Rheum Dis 1976; 35: 361–4.
106. Harris ED Jr. The clinical features of rheumatoid arthritis. In: Kelley WM, Harris ED Jr, Ruddy S, Sledge C, eds. Textbook of rheumatology. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1989:943–81.
107. Thompson PW, Silman AJ, Kirwan JR, Currey HL. Articular indices of joint inflammation in rheumatoid arthritis: correlation with the acute-phase response. Arthritis Rheum 1987; 30: 618–23.
108. Guerne P-A, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83: 585–92.
109. Winchester RJ, Koffler D, Litwin SD, Kunkel HG. Observations on the eosinophilia of certain patients with rheumatoid arthritis. Arthritis Rheum 1971; 14: 650–65.
110. Hutchinson RM, Davis P, Jayson MI. Thrombocytosis in rheumatoid arthritis. Ann Rheum Dis 1976; 35: 138–42.
111. Anderson JJ, Felson DT, Meenan RF, Williams HJ. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1989; 32: 1093–9.
112. Harris ED Jr. Management of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1989:982–92.
113. Klippel JH, Strober S, Wofsy D. New therapies for the rheumatic diseases. Bull Rheum Dis 1989; 38: 1–8.
114. Lorig KR, Lubeck D, Kraines RG, Seleznick M, Holman HR. Outcomes of self-help education for patients with arthritis. Arthritis Rheum 1985; 28: 680–5.
115. Merry P, Winyard PG, Morris CJ, Grootveld M, Blake DR. Oxygen free radicals, inflammation, and synovitis: the current status. Ann Rheum Dis 1989; 48: 864–70.
116. Pike MC. Antiinflammatory effects of dietary lipid modification. J Rheumatol 1989; 16: 718–20.
117. Sperling RI, Weinblatt M, Robin JL, et al. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum 1987; 30: 988–97.
118. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265–71.
119. Kremer JM, Jubiz W, Michalek A, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 1987; 106: 497–503.
120. Kremer J, Lawrence D, Jubiz W, et al. Different doses of fish oil fatty acid supplementation in rheumatoid arthritis (RA): a prospective double-blinded randomized study. Arthritis Rheum 1988; 31: 530.
121. Paulus HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WM, Harris ED Jr, Ruddy S, Sledge C, eds. Textbook of rheumatology. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1989:765–91.
122. Harris ED Jr, Emkey RD, Nichols JE, Newberg A. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983; 10: 713–21.
123. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 1989; 48: 535–8.
124. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis: indications, contraindications, efficacy, and safety. Ann Intern Med 1987; 107: 358–66.
125. Gordon DA. Gold compounds. In: Kelley WM, Harris ED Jr, Ruddy S, Sledge C, eds. Textbook of rheumatology. 3rd ed. Vol. 1. Philadelphia: W.B. Saunders, 1989:804–23.
126. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints: stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989; 83: 1267–76.
127. Burmester GR, Dimitriu-Bona A, Waters SJ, Winchester RJ. Identification of three major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol 1983; 17: 69–82.
128. Goto M, Sasano M, Yamanaka H, et al. Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest 1987; 80: 786–96.
129. Woolley DE, Harris ED Jr, Mainardi CL, Brinckerhoff CE. Collagenase immunolocalization in cultures of rheumatoid synovial cells. Science 1978; 200: 773–5.
130. Stephenson ML, Goldring MB, Birkhead JR, Krane SM, Rahmsdorf HJ, Angel P. Stimulation of procollagenase synthesis parallels increases in cellular procollagenase mRNA in human articular chondrocytes exposed to recombinant interleukin 1 β or phorbol ester. Biochem Biophys Res Commun 1987; 144: 583–90.
131. Conca W, Kaplan PB, Krane SM. Increases in levels of procollagenase messenger RNA in cultured fibroblasts induced by human recombinant interleukin 1β or serum follow c-jun expression and are dependent on new protein synthesis. J Clin Invest 1989; 83: 1753–7.
132. Eisen AA, Bauer EA, Stricklin GP, Seltzer JL, Koob TJ, Jeffrey JJ. Control of human skin collagenase activity. In: McCabe BF, Sadé J, Abramson M, eds. Cholesteatoma: First International Conference. Birmingham, Ala.: Aesculapius Publishing, 1977:115–23.
133. Carmichael DF, Sommer A, Thompson RC, et al. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci U S A 1986; 83: 2407–11.
134. Pinals RS. Survival in rheumatoid arthritis. Arthritis Rheum 1987; 30: 473–5.
135. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986; 29: 494–500.
136. Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7–13.
137. Callahan LF, Pincus T. Formal education level as a significant marker of clinical status in rheumatoid arthritis. Arthritis Rheum 1988; 31: 1346–57.
138. Regan-Smith MG, O'Connor GT, Kwoh CK, Brown LA, Olmstead EM, Burnett JB. Lack of correlation between the Steinbrocker staging of hand radiographs and the functional health status of individuals with rheumatoid arthritis. Arthritis Rheum 1989; 32: 128–33.
139. Withrington RH, Teitsson I, Valdimarsson H, Seifert MH. Prospective study of early rheumatoid arthritis. II. Association of rheumatoid factor isotypes with fluctuations in disease activity. Ann Rheum Dis 1984; 43: 679–85.
140. Ochi T, Yonemasu K, Iwase R, Sasaki T, Tsuyama K, Ono K. Serum C1q levels as a prognostic guide to articular erosions in patients with rheumatoid arthritis. Arthritis Rheum 1984; 27: 883–7.
141. Hørslev-Peterson K, Bentsen KD, Junker P, Lorenzen I. Serum aminoterminal type III procollagen peptide in rheumatoid arthritis: relationship to disease activity, treatment, and development of joint erosions. Arthritis Rheum 1986; 29: 592–9.
142. Black D, Marabani M, Sturrock RD, Robins SP. Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 641–4.
143. Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989; 32: 221–9.
144. Gilkeson G, Polisson R, Sinclair H, et al. Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of magnetic resonance imaging. J Rheumatol 1988; 15: 1361–6.
145. Salisbury MD, Nottage WM. A new evaluation of gross pathologic changes and concepts of rheumatoid articular cartilage degeneration. Clin Orthop 1985; 199: 242–7.
146. Williams IA, Baylis EM, Shipley ME. A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. Lancet 1982; 2: 237–4.
147. Gaston JS, Strober S, Solovera JJ, et al. Dissection of the mechanisms of immune injury in rheumatoid arthritis, using total lymphoid irradiation. Arthritis Rheum 1988; 31: 21–30.
148. Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study. Ann Intern Med 1988; 109: 863–9.
149. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind placebo controlled study in 52 patients. Ann Rheum Dis 1988; 47: 127–33.
150. Dougados M, Duchesne L, Awada H, Amor B. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 550–6.
151. Folkman J, Weisz PB, Joullié MM, Li WW, Ewing WR. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490–3.
152. Sany J, Clot J, Bonneau M, Andary M. Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis. Arthritis Rheum 1982; 25: 17–24.
153. Kyle V, Coughlan RJ, Tighe H, Waldmann H, Hazleman BL. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 428–9.
154. Herzog C, Walker C, Müller W, Riethmuller G, Muller W, Pichler WJ. anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells. J Autoimmun 1989; 2: 627–42.
155. Walker C, Herzog C, Rieber P, et al. anti-CD4 antibody treatment of patients with rheumatoid arthritis. II. Effect of in vivo treatment on in vitro proliferative response of CD4 cells. J Autoimmun 1989; 2: 643–9.
156. Shmerling RH, Trentham DE. Prolonged improvement in refractory rheumatoid arthritis after brief antithymocyte globulin therapy of brief duration. Arthritis Rheum 1989; 32: 1495–6.
157. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-β. Science 1988; 242: 97–9.
158. Herzog C, Walker C, Pichler WJ. New therapeutic approaches in rheumatoid arthritis. Concepts Immunopathol 1989; 7: 79–105.
159. Sledge CB, Zuckerman JD, Zalutsky MR, et al. Treatment of rheumatoid synovitis of the knee with intraarticular injection of dysprosium 165-ferric hydroxide macroaggregates. Arthritis Rheum 1986; 29: 153–9.
160. 165–ferric hydroxide macroaggregates in rheumatoid knees unresponsive to initial injection. Arthritis Rheum 1988; 31: 789–92.